RxDoctor Payments Data

Naveed Wagle, MD

Neurology · Santa Monica, CANPI 1871754655

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,079 of the $4,446 with a category attached, or 69.3%. 35 manufacturers reported payments, led by Boehringer Ingelheim at 30.3% of the total.

$4,446in general payments, 2019–2025

Across 90 payments — averaging $49.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Novocure Inc.$832
  • Boehringer Ingelheim International GmbH$299
  • Springworks Therapeutics, Inc.$243
  • GT Medical Technologies, Inc$211
  • Merck$144
  • plus $1K from 29 others
$1,830,981in research payments, 2019–2025

Across 215 payments — averaging $8516.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$828K
  • Boehringer Ingelheim$357K
  • Bavarian Nordic A/s$219K
  • AbbVie$219K
  • Elekta, Inc.$99K
  • Jazz Pharmaceuticals Inc.$49K
  • plus $60K from 4 others

What the payments were for

  • Speaking & faculty fees$2997%
  • Travel & lodging$1,06824%
  • Food & beverage$3,07969%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,446 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$93,894
Medicare patients
151
Services billed
845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lacosamide16$1,107
Levetiracetam20$457

Paid to pharmacies, not to this prescriber.

Other neurology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →